Insider Selling: Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) CFO Sells $316,787.52 in Stock

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) CFO Benjamin Hohl sold 6,018 shares of Bitwise MARA Option Income Strategy ETF stock in a transaction that occurred on Friday, July 17th. The shares were sold at an average price of $52.64, for a total value of $316,787.52. Following the sale, the chief financial officer directly owned 46,054 shares in the company, valued at approximately $2,424,282.56. The trade was a 11.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl also recently made the following trade(s):

• On Wednesday, June 17th, Benjamin Hohl sold 6,018 shares of Bitwise MARA Option Income Strategy ETF stock. The stock was sold at an average price of $43.80, for a total transaction of $263,588.40.

Bitwise MARA Option Income Strategy ETF Stock Performance

Shares of NYSEARCA:IMRA traded down $0.06 during midday trading on Tuesday, reaching $14.46. 890 shares of the company’s stock traded hands, compared to its average volume of 4,858. Bitwise MARA Option Income Strategy ETF has a one year low of $11.99 and a one year high of $43.70. The stock has a 50 day moving average of $16.56 and a 200 day moving average of $15.49. The company has a market cap of $1.88 million, a price-to-earnings ratio of 289.20 and a beta of 2.74.

Bitwise MARA Option Income Strategy ETF Company Profile

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2?related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.